Human Genome anthax drug needs new study, panel says

Published



Human Genome Sciences Inc.’s experimental drug raxibacumab needs more testing for use against inhaled anthrax, a U.S. panel said.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.